[HTML][HTML] Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20

DM McCraw, JK O'Donnell, KA Taylor, SM Stagg… - Virology, 2012 - Elsevier
Virology, 2012Elsevier
The use of adeno-associated virus (AAV) as a gene therapy vector is limited by the host
neutralizing immune response. The cryo-electron microscopy (EM) structure at 8.5 Å
resolution is determined for a complex of AAV-2 with the Fab'fragment of monoclonal
antibody (MAb) A20, the most extensively characterized AAV MAb. The binding footprint is
determined through fitting the cryo-EM reconstruction with a homology model following
sequencing of the variable domain, and provides a structural basis for integrating diverse …
The use of adeno-associated virus (AAV) as a gene therapy vector is limited by the host neutralizing immune response. The cryo-electron microscopy (EM) structure at 8.5Å resolution is determined for a complex of AAV-2 with the Fab’ fragment of monoclonal antibody (MAb) A20, the most extensively characterized AAV MAb. The binding footprint is determined through fitting the cryo-EM reconstruction with a homology model following sequencing of the variable domain, and provides a structural basis for integrating diverse prior epitope mappings. The footprint extends from the previously implicated plateau to the side of the spike, and into the conserved canyon, covering a larger area than anticipated. Comparison with structures of binding and non-binding serotypes indicates that recognition depends on a combination of subtle serotype-specific features. Separation of the neutralizing epitope from the heparan sulfate cell attachment site encourages attempts to develop immune-resistant vectors that can still bind to target cells.
Elsevier